Avanos Medical (AVNS) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 36.84%. A quarter ago, it was expected that this medical technology company would post earnings of $0.40 per share when it actually produced earnings of $0.43, delivering a surprise of 7.50%.Over the last four quart ...

Financial Data and Key Metrics Changes - The company achieved sales of approximately $168 million for the first quarter, with organic sales up 2.8% compared to the previous year [8][9] - Adjusted diluted earnings per share were $0.26, and adjusted EBITDA was approximately $22 million, with adjusted gross margins at 56.7% [9] - The balance sheet remains strong with $97 million in cash and $107 million in debt as of March 31 [9] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems segment grew almost 9% organically compared to the prior year, reaffirming its leading position in long-term, short-term, and neonatal internal feeding [13] - The Pain Management and Recovery segment saw normalized organic sales up 2.4%, with the radiofrequency ablation business posting near double-digit growth [15][16] - The hyaluronic acid injections and intravenous infusion product lines reported a decline of over 30% due to pricing pressures [18] Market Data and Key Metrics Changes - The company anticipates a softer Q2 for the Specialty Nutrition Systems segment due to distributor order timing but remains confident in its strength for the rest of the year [19] - The impact of tariffs is expected to be significant, with an estimated $15 million in incremental tariff-related manufacturing costs for the year [20][22] Company Strategy and Development Direction - The company is focused on transformation efforts around portfolio, organization structure, and cost management to enhance growth [6][10] - Strategic M&A opportunities are being pursued to align with return criteria, with two smaller transactions already closed this year [10] - The organizational focus has been refined to improve operating processes and capitalize on growth opportunities [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong start to the year, particularly in strategic segments, despite a dynamic economic environment [23] - The revised adjusted EPS estimate reflects a reasonable view of the tariff impact on full-year results [23] - The company is actively monitoring the tariff situation and executing initiatives to reduce risks [23] Other Important Information - The company has transitioned to reporting under two operating segments: Specialty Nutrition Systems and Pain Management and Recovery [11] - A disciplined cost management culture has been embedded to help offset tariff pressures [19] Q&A Session Summary Question: Thoughts on second quarter performance relative to the first - Management indicated that while Q2 may see a slight decline due to distributor order dynamics, they maintain confidence in full-year guidance [28][30] Question: Insights on leadership experience and strategic focus - The new CEO emphasized a focus on optimizing commercial strategies and partnerships to enhance market position [35][36] Question: Clarification on tariff assumptions and impacts - Management provided details on expected tariff-related costs and mitigation strategies, including leveraging international agreements [41][44]

Avanos Medical, Inc. First Quarter 2025 Results [Executive Summary and Financial Highlights](index=1&type=section&id=Executive%20Summary%20and%20Financial%20Highlights) Avanos Medical Q1 2025 net sales $167.5 million (+0.8%), net income $6.6 million, adjusted diluted EPS $0.26, showing improved profitability - The new CEO, David Pacitti, noted that transformation efforts in portfolio, structure, and cost management have positioned Avanos for **accelerated growth, improved execution, and enhanced margin profiles**[3](index=3&type=chunk) Q1 2025 Financial Highlights vs. Q1 2024 | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Net Sales | $167.5M | $166.1M | +0.8% | | Net Income (from continuing ops) | $6.6M | $0.5M | +1220% | | Adjusted Net Income | $12.0M | $10.1M | +18.8% | | Diluted EPS | $0.14 | $0.01 | +1300% | | Adjusted Diluted EPS | $0.26 | $0.22 | +18.2% | | Adjusted EBITDA | $21.6M | $21.6M | 0.0% | [Consolidated Operating Results](index=1&type=section&id=Consolidated%20Operating%20Results) Q1 2025 net sales rose 0.8% to $167.5 million, organic sales up 2.8%; gross margin fell to 53.6%, but operating income doubled to $10.3 million from reduced expenses - Organic net sales grew **2.8%** year-over-year, adjusted for foreign currency effects and the decision to exit certain low-return revenue streams[5](index=5&type=chunk) - Adjusted gross margin fell to **56.7%** from **59.8%** in the prior year, impacted by unfavorable pricing for hyaluronic acid ("HA") products[6](index=6&type=chunk) - Selling and general expenses as a percentage of net sales decreased to **45.2%** from **50.3%** a year ago, mainly due to lower costs from restructuring and divestiture activities[6](index=6&type=chunk) - Operating income increased to **$10.3 million** compared to **$4.0 million** in the prior year period. On an adjusted basis, operating income was **$17.1 million**, up from **$16.3 million**[8](index=8&type=chunk) [Business Segment Performance](index=2&type=section&id=Business%20Segment%20Performance) SNS sales grew 6.9% to $101.1 million with 37% operating income rise; PM&R sales flat at $56.2 million, swinging to $0.2 million operating profit Q1 2025 Net Sales by Segment (in millions) | Segment | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | Specialty Nutrition Systems | $101.1 | $94.6 | +6.9% | | Pain Management and Recovery | $56.2 | $56.3 | -0.2% | | Corporate and Other | $10.2 | $15.2 | -32.9% | | **Total Net Sales** | **$167.5** | **$166.1** | **+0.8%** | Q1 2025 Operating Income (Loss) by Segment (in millions) | Segment | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | Specialty Nutrition Systems | $21.1 | $15.4 | +37.0% | | Pain Management and Recovery | $0.2 | $(2.1) | N/A | | Corporate and Other | $(11.0) | $(9.3) | +18.3% | | **Total Operating Income** | **$10.3** | **$4.0** | **+157.5%** | [Specialty Nutrition Systems (SNS)](index=2&type=section&id=Specialty%20Nutrition%20Systems%20%28SNS%29) SNS net sales reached $101.1 million (+6.9%), driven by 8.7% volume growth, with operating income rising to $21.1 million (20.9% margin) from higher volume and lower SG&A - SNS net sales reached **$101.1 million**, with strong **8.7% volume growth** driven by continued demand in both enteral feeding and neonate solutions categories[10](index=10&type=chunk) - Operating income for the SNS segment was **$21.1 million**, or **20.9%** of its net sales, due to higher volume and reduced selling, general and administrative expenses[10](index=10&type=chunk) [Pain Management and Recovery (PM&R)](index=2&type=section&id=Pain%20Management%20and%20Recovery%20%28PM%26R%29) PM&R net sales were $56.2 million; 8.2% RFA growth offset by 9.3% surgical pain decline and currency, resulting in $0.2 million operating profit from reduced SG&A - Net sales of radiofrequency ablation (RFA) products grew **8.2%**, driven by momentum in generator sales (ESENTEC and TRIDENT lines)[11](index=11&type=chunk) - Surgical pain and recovery net sales declined **9.3%**, which was in line with company expectations[11](index=11&type=chunk) - The segment achieved an operating profit of **$0.2 million**, compared to a loss of **$2.1 million** last year, due to lower SG&A expenses[11](index=11&type=chunk) [Cash Flow and Balance Sheet](index=2&type=section&id=Cash%20Flow%20and%20Balance%20Sheet) As of March 31, 2025, cash was $97.0 million; operating cash flow was a $25.7 million inflow, reversing an $8.0 million outflow, leading to $19.0 million free cash flow, with total debt reduced to $107.4 million - Cash on hand was **$97.0 million** as of March 31, 2025, down from **$107.7 million** at year-end 2024[12](index=12&type=chunk) - Total debt outstanding was reduced by **$27.3 million** during the quarter, from **$134.7 million** to **$107.4 million**[12](index=12&type=chunk) Cash Flow Summary (in millions) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Cash flow from operations | $25.7 | $(8.0) | | Free cash flow | $19.0 | $(12.1) | [2025 Outlook](index=2&type=section&id=2025%20Outlook) Avanos maintains 2025 revenue guidance of $665 million-$685 million but lowered adjusted diluted EPS forecast to $0.75-$0.95 due to anticipated negative tariff impacts - The company is maintaining its 2025 estimated revenue of between **$665 million** and **$685 million**[13](index=13&type=chunk) - The estimated adjusted diluted earnings per share range for 2025 has been lowered to between **$0.75** and **$0.95**, primarily due to the impact of recently announced tariffs[13](index=13&type=chunk) - The ultimate impact from tariffs remains uncertain and depends on factors like final tariff rates on China-origin goods, mitigation efforts, and the level of imports from China and Mexico[14](index=14&type=chunk) 2025 Adjusted Diluted EPS Outlook Reconciliation | Metric | Estimated Range | | :--- | :--- | | Diluted earnings per share (GAAP) | $0.33 to $0.56 | | Intangibles amortization | $0.25 to $0.24 | | Post RH-Divestiture transition charges | $0.12 to $0.10 | | Other | $0.05 to $0.05 | | **Adjusted diluted earnings per share (non-GAAP)** | **$0.75 to $0.95** | [Financial Statements and Supplemental Data](index=5&type=section&id=Financial%20Statements%20and%20Supplemental%20Data) [Condensed Consolidated Income Statements](index=5&type=section&id=Condensed%20Consolidated%20Income%20Statements) Details revenues, costs, expenses, net income, and EPS for Q1 2025 compared to Q1 2024 Condensed Consolidated Income Statement (in millions, except per share) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Sales | $167.5 | $166.1 | | Gross Profit | $89.8 | $94.8 | | Operating Income | $10.3 | $4.0 | | Income from Continuing Operations | $6.6 | $0.5 | | Net Income (Loss) | $6.6 | $(0.9) | | Diluted EPS (Continuing ops) | $0.14 | $0.01 | [Condensed Consolidated Balance Sheets](index=15&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Presents the company's financial position, detailing assets, liabilities, and equity as of March 31, 2025, compared to December 31, 2024 Condensed Consolidated Balance Sheet (in millions) | Metric | Mar 31, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | **ASSETS** | | | | Cash and cash equivalents | $97.0 | $107.7 | | Total Current Assets | $352.4 | $393.4 | | TOTAL ASSETS | $1,107.8 | $1,154.2 | | **LIABILITIES & EQUITY** | | | | Total Current Liabilities | $137.2 | $165.9 | | Long-Term Debt | $98.0 | $125.3 | | TOTAL LIABILITIES | $268.4 | $325.7 | | Stockholders' Equity | $839.4 | $828.5 | | TOTAL LIABILITIES AND EQUITY | $1,107.8 | $1,154.2 | [Condensed Consolidated Cash Flow Statements](index=16&type=section&id=Condensed%20Consolidated%20Cash%20Flow%20Statements) Details cash inflows and outflows from operating, investing, and financing activities for Q1 2025 and Q1 2024 Condensed Consolidated Cash Flow Statement (in millions) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Cash Provided by (Used in) Operating Activities | $25.7 | $(8.0) | | Cash Used in Investing Activities | $(9.1) | $(2.0) | | Cash Used in Financing Activities | $(29.1) | $(0.7) | | Decrease in Cash and Cash Equivalents | $(10.7) | $(11.9) | | Cash and Cash Equivalents - End of Period | $97.0 | $75.8 | [Non-GAAP Reconciliations](index=3&type=section&id=Non-GAAP%20Reconciliations) Provides detailed reconciliations of GAAP to non-GAAP financial measures, including adjusted gross profit, operating income, net income, EPS, EBITDA, and free cash flow, for a clearer view of ongoing operational performance - The company uses non-GAAP measures to **evaluate historical and prospective financial performance, allocate resources, and measure operational performance of business units**. These measures are also used for **setting incentive compensation goals**[16](index=16&type=chunk)[17](index=17&type=chunk) Reconciliation of Net Income to Adjusted EBITDA (in millions) | Metric | Q1 2025 | Q1 2024 (Continuing Ops) | | :--- | :--- | :--- | | Net income (loss) | $6.6 | $0.5 | | Interest expense, net | $0.6 | $2.5 | | Income tax provision | $3.1 | $1.0 | | Depreciation & Amortization | $9.6 | $11.4 | | **EBITDA** | **$19.9** | **$15.4** | | Restructuring & Divestiture Charges | $3.1 | $4.6 | | Other Adjustments (EU MDR, Legal, etc.) | $(1.4) | $1.6 | | **Adjusted EBITDA** | **$21.6** | **$21.6** | Reconciliation of GAAP to Non-GAAP Diluted EPS | Metric | Q1 2025 | Q1 2024 (Continuing Ops) | | :--- | :--- | :--- | | Diluted EPS, as reported (GAAP) | $0.14 | $0.01 | | Adjustments (Restructuring, Amortization, etc.) | $0.12 | $0.21 | | **Diluted EPS, as adjusted (Non-GAAP)** | **$0.26** | **$0.22** |

Core Viewpoint - Avanos Medical, Inc. will host a conference call to discuss its financial results and business highlights for Q1 2025 on May 6, 2025, at 9 a.m. ET, with a news release to be issued before market opening on the same day [1]. Group 1 - The conference call will be led by key executives including the CEO, interim CFO, senior VP of strategy and corporate development, and the board chairman [2]. - Participants can join the conference call via a registration link or by dialing specific phone numbers [3]. - A simultaneous webcast of the call will be available on the Avanos Medical website, with a replay accessible within two hours post-call for one week [4]. Group 2 - Avanos Medical is a medical technology company focused on providing clinically superior medical device solutions, addressing critical healthcare needs such as nutrition support and opioid reduction [5]. - The company is headquartered in Alpharetta, Georgia, and holds leading market positions in various product categories [5].

Avanos Medical, Inc. (AVNS) is set to assume direct control of sales and distribution for its MIC-KEY enteral feeding products in the United Kingdom, effective July 2025. This marks a strategic departure from its longstanding reliance on Vygon UK, which has served as the product distributor for nearly three decades.The decision underscores Avanos' intention to strengthen its market presence by establishing direct relationships with healthcare providers and refining its service delivery. By internalizing sal ...

Company Overview - Avanos Medical, Inc. is a global medical technology company focused on delivering clinically superior medical device solutions, headquartered in Alpharetta, Georgia [4] - The company is committed to addressing important healthcare needs, including providing nutrition to patients and reducing opioid use [4] Strategic Move - Avanos will take direct responsibility for the sales and distribution of its MIC-KEY enteral feeding products in the UK, effective July 25, 2025 [1] - This transition aims to enhance product availability and provide a seamless experience for healthcare providers and patients [1][2] Relationship with Distributors - Vygon UK has been a distributor of MIC-KEY products for 29 years, supporting hospitals and patients across the UK [2] - Avanos' decision to manage sales directly is intended to strengthen relationships with healthcare professionals and ensure continuity of care [3] Product Information - MIC-KEY products deliver enteral nutrition through a low-profile feeding tube and have been trusted by clinicians and patients for over 25 years [3] - The products are sold in over 60 countries across six continents, highlighting their global reach and acceptance [3] Transition Support - Avanos is committed to ensuring a smooth transition and will provide ongoing communication and support to customers during this period [4] - Healthcare providers currently purchasing MIC-KEY products through Vygon will receive guidance on how to order from Avanos with minimal disruption [4]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 近日， 西门子医疗宣布瓦里安美洲区总裁John Kowal将接替David Pacitti ，担任西门子医疗解决方案（美国）公 司总裁兼美洲区负责人。与此同时， David Pacitti正式转任Avanos Medical首席执行官（CEO） 。 # 高管变动详情 John Kowal将接替David Pacitti，担任西门子医疗解决方案（美国）公司总裁兼美洲区负责人，任命将于2025年4月14 日生效。 John Kowal于2005年加入瓦里安，从地区销售经理逐步晋升至美洲区总裁。 他在瓦里安任职期间，成功推动了客户 满意度和忠诚度的提升，制定了有效的业务战略，并带领团队实现了收入和订单预算的突破。此外，他还致力于推 动癌症治疗的普及，特别是在健康不平等地区。 在加入西门子医疗之前，Pacitti曾在 雅培血管公司 担任领导职务，包括担任美国商业运营、销售和市场营销的部门 副总裁。他负责监督雅培公司多个关键产品的推出，包括其首个药物洗 ...

Core Viewpoint - Avanos Medical, Inc. has appointed David Pacitti as the new CEO, effective April 14, 2025, to lead the company in its next phase of growth and success [1][3]. Company Overview - Avanos Medical is a medical technology company headquartered in Alpharetta, Georgia, focused on delivering clinically superior medical device solutions to improve patient quality of life [6]. - The company addresses critical healthcare needs, including providing nutrition support and reducing opioid use during patient recovery [6]. Leadership Background - David Pacitti has a distinguished career in the healthcare sector, previously serving as president of Siemens Medical Solutions USA and Head of the Americas for Siemens Healthineers, where he drove strategic growth and operational excellence [2][3]. - Prior to Siemens, Pacitti held leadership roles at Abbott Vascular, overseeing significant product launches and commercial operations [3]. Strategic Vision - Pacitti expressed his commitment to building on Avanos' success and driving long-term value for stakeholders, emphasizing the company's strong portfolio of market-leading products [5].

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Avanos Medical, Inc. (AVNS) is a medical technology company focusing on delivering medical device solutions. The Zacks Consensus Estimate for its current year earnings has been revised 18.5% downward over the last 60 days.CSX Corporation (CSX) is a rail-based freight transportation services company. The Zacks Consensus Estimate for its current year earnings has been revised 9.4% downward over the last 60 days.Constellation Brands, Inc ...

Avanos Medical, Inc. (AVNS) reported fourth-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 43 cents, up 19.4% year over year. The bottom line surpassed the Zacks Consensus Estimate by 7.5%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP loss per share from continuing operations in the quarter under review was $8.63 against the year-ago period’s EPS of 24 cents.Full-year 2024 adjusted EPS was $1.35, up 31.1% from a year ago. The metric topped the Zack ...